Modicare off to a mixed start, says analyst GlobalData

27 November 2018

A research note from industry analyst GlobalData concludes that India’s new national insurance scheme Ayushman Bharat has potential to be a “game changer,” while warning that there are “policy issues which need to be addressed by the government to make it sustainable for all the stakeholders.”

The program is designed to cover the hospitalization costs for poorer rural families, and certain occupational categories of urban workers, up to $7,000.

Dubbed “Modicare,” after Indian Prime Minister Narendra Modi, the scheme has been criticized for the amount of money set aside to cover costs, just 200 billion rupees, or around a fifth of 1% of India’s GDP.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK